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Liver transplantation has been performed for a wide
variety of rare hepatic tumors. The anecdotal nature of
this experience makes evidence-based decisions re-
garding suitability for transplantation very challenging.
The largest reports of transplantation for tumors other
than hepatocellular carcinoma and cholangiocarci-
noma have been for neuroendocrine tumors. Hepatic
metastases are present in approximately 75% of pa-
tients at the time a neuroendocrine tumor is diagnosed,
and cure by liver transplantation (LT) is rare.
TUMORS
Noncarcinoid Neuroendocrine Tumors
Outcomes in patients with noncarcinoid tumors are
inferior to those in patients with carcinoid tumors lim-
ited to the liver.1 The largest series of patients with
noncarcinoid tumors, a French multicenter experience,
had survival rates of 38, 15, and 8% at 1, 3, and 4 years,
respectively, with no disease-free survivors at 5 years.1
Reports since then have failed to document better out-
comes. Although LT is not curative, it probably offers
substantial palliative benefit to selected patients. Nev-
ertheless, given the overall dismal outcomes, it does not
appear wise to offer LT to these patients as a standard
Model for End-Stage Liver Disease (MELD) exception.
Carcinoid Neuroendocrine Tumors
In the French experience,1 the survival rate for meta-
static carcinoid tumors was 80, 80, and 69% at 1, 3,
and 5 years, respectively. In comparison, the 5-year
survival rate after nontransplant treatment of neuroen-
docrine tumors is 25 to 35%. Although this is not a fair
comparison because of selection bias, it does suggest
that selected patients with this disease may benefit
from LT.
Patients should be excluded if they have evidence of
extrahepatic tumor deposits because these patients
cannot be cured by LT. Ideally, the primary tumor
should have been removed because tumor recurrence
after upper abdominal exenteration is associated with
high morbidity and has not been shown to improve the
tumor-free survival rate. A bone scan and/or skeletal
survey is important because the next most frequent site
of distant metastasis after the liver is bone. It is sug-
gested that LT be considered when patients are symp-
tomatic and when tumor has failed to respond to other
available treatments after presentation to the Regional
Review Board.
Sarcoma
Although there are anecdotal cases of patients with
long-term survival after LT for primary angiosarcoma of
the liver, the preponderance of data indicates very poor
survival and that cure is not possible.2 These patients
should not receive additional priority for LT as a stan-
dard MELD exception.
Hepatic Epithelioid Hemangioendothelioma
These tumors arise from the vascular endothelium and
must be distinguished from sarcoma. Those affected
are predominantly young adults, particularly young
women. The extent of tumor involvement is difficult to
define radiologically. Diagnosis is confirmed by positive
immunohistochemical staining for factor VIII. In the
first year of the MELD and Pediatric End-Stage Liver
Disease policy, 16 requests were made for exceptions
that were based on this diagnosis, and 14 were granted.
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Treatment can include observation alone, chemo-
therapy, resection, or LT, with long-term survival re-
ported for each of these treatment options. The results
for LT are quite good, despite the fact that the tumor is
often widespread at the time of diagnosis. A 5-year
tumor-free survival rate of 60% has been reported.3
Successful treatment of patients with extrahepatic dis-
ease has been described, and metastatic spread at the
time of LT does not appear to correlate with posttrans-
plantation survival.4-6 Therefore, this tumor is one of
the circumstances where LT in the presence of extrahe-
patic disease may be justified. The highly variable clin-
ical behavior of this tumor makes it impossible to pro-
vide objective data on when LT should be performed
and how long the window of opportunity for LT is. Cur-
rent opinion is that treatment should be individualized
depending on symptoms and the rate of disease pro-
gression.
Biliary Cystadenocarcinoma
This tumor, which can arise in association with Caroli’s
disease, must be distinguished from benign biliary cys-
tadenoma. It is usually multilocular, but unilocular
cases have been reported. In general, this tumor is
amenable to surgical resection. There are anecdotal
cases of successful LT for this tumor, but long-term
follow-up data are not available for patients treated
with LT for this indication.2
Hepatic Adenoma in Patients With Glycogen
Storage Disease
Multiple hepatic adenomas are seen in approximately
half of patients with type I glycogen storage disease, and
in approximately one-fourth of patients with type III
glycogen storage disease. Rupture and malignant
transformation of these tumors have been reported, but
the risk of these complications is unclear.7 Determining
when malignant transformation has occurred can be
problematic, making management of these patients dif-
ficult. LT is indicated when malignant transformation is
suspected or proven and curative resection is not pos-
sible.
SYNTHESIS OF AVAILABLE DATA
There are insufficient data to justify additional priority
for candidates with noncarcinoid neuroendocrine tu-
mors, hepatic sarcomas, or biliary cystadenocarci-
noma. The available data justify additional priority for
candidates with carcinoid tumors that are limited to the
liver, hepatic epithelioid hemangioendotheliomas (even
with extrahepatic spread), and hepatic adenomas in the
setting of glycogen storage disease. A more efficient
mechanism to assemble experience in LT for these tu-
mors is needed.
PROPOSAL FOR STANDARDIZED MELD
EXCEPTIONS FOR CANDIDATES WITH
UNCOMMON TUMORS
At this time, we propose that candidates with uncom-
mon tumors continue to be addressed by the Regional
Review Boards and additional MELD priority assigned
on a case-by-case basis. Additional MELD priority
should not be automatically granted at this time.
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